How to transfer my Strattera prescription to Illinois

If you’re considering treatment for ADHD but concerned about the limitations of telehealth prescribing, you’re not alone. Many people wonder: Can I actually get ADHD medication—especially non-stimulants like Strattera—through a virtual visit?

The short answer is yes. Non-stimulant ADHD medications can be prescribed via telehealth in all 50 states, with far fewer restrictions than their stimulant counterparts. Understanding how this works, what the current regulations allow, and what to expect from your virtual care can help you access effective treatment more easily.

Understanding Non-Stimulant ADHD Medications

What Are Non-Stimulant ADHD Medications?

Non-stimulant medications treat ADHD through different mechanisms than traditional stimulants like Adderall or Ritalin. The most commonly prescribed non-stimulant is Strattera (atomoxetine), which works by increasing norepinephrine levels in the brain to improve focus and impulse control.

Key fact: Strattera is not a controlled substance by the DEA, meaning it doesn’t carry the same federal prescribing restrictions as stimulant medications. This single distinction makes telehealth prescribing significantly more straightforward.

Why Choose a Non-Stimulant?

Non-stimulants may be the right choice if you:

• Have a history of substance use concerns
• Experience intolerable side effects from stimulants (like increased anxiety or sleep problems)
• Have certain cardiovascular conditions that make stimulants risky
• Prefer a medication without abuse potential
• Need consistent 24-hour symptom coverage

While Strattera typically takes 4–6 weeks to reach full effectiveness (compared to stimulants that work the same day), many patients find the steady, non-fluctuating coverage beneficial for managing symptoms throughout the day and evening.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

The Federal Landscape: DEA Rules and Telehealth

Current Status Through 2025

As of December 2025, the DEA has extended pandemic-era telehealth flexibilities for prescribing controlled substances (Schedules II–V) through December 31, 2025. This ‘Third Temporary Extension’ allows healthcare providers to prescribe controlled ADHD medications—including stimulants—via telehealth without a prior in-person examination.

However, here’s what matters for non-stimulant treatment: These federal restrictions never applied to Strattera in the first place. Since atomoxetine isn’t a controlled substance, the Ryan Haight Act’s in-person exam requirement doesn’t govern its prescription. This means telehealth providers could—and can—prescribe Strattera based solely on a comprehensive video evaluation, both before and after the COVID-era flexibilities.

What Happens in 2026?

The DEA is expected to announce either a fourth extension or finalize new permanent telehealth prescribing rules. A ‘Special Registration’ system has been proposed that would create permanent pathways for controlled substance prescribing via telehealth with additional safeguards.

For non-stimulant patients, this uncertainty matters less. Even if controlled substance flexibilities expire, your access to medications like Strattera through telehealth should remain unaffected, as these medications fall outside DEA scheduling.

State-by-State Considerations

While federal law sets the baseline, individual states add their own requirements. The good news: no state outright prohibits telehealth treatment for ADHD. However, certain states have implemented additional rules worth knowing about.

States With Minimal Restrictions

California, Illinois, Pennsylvania, and Georgia allow telehealth ADHD treatment with no mandatory in-person visits for non-controlled medications. Providers must simply maintain appropriate standards of care and be licensed in your state.

New Hampshire recently updated its laws (effective August 2025) to remove prior in-person requirements, now only requiring at least an annual follow-up evaluation for patients on controlled medications—making it easier than ever to start treatment virtually.

States With Special Considerations

Florida generally prohibits telehealth prescribing of Schedule II stimulants—unless prescribed for a psychiatric disorder. Since ADHD qualifies as a psychiatric condition, stimulants can be prescribed via telehealth in Florida under this exception. For Strattera and other non-controlled medications, there are no special restrictions.

Texas is highly telehealth-friendly for mental health care, with no blanket in-person requirement for ADHD treatment. However, nurse practitioners and physician assistants in Texas cannot prescribe Schedule II stimulants in outpatient settings (only in hospitals or hospice care). Physicians can prescribe both stimulants and non-stimulants via telehealth, and NPs/PAs can freely prescribe non-controlled medications like Strattera.

New York reinstated in-person prerequisites for prescribing controlled substances via telemedicine in 2025. This means an initial in-person evaluation is required before prescribing stimulants like Adderall. However, this rule does not apply to Strattera since it’s not a controlled substance—non-stimulant prescriptions can proceed via telehealth alone.

Alabama maintains one of the strictest telehealth policies, requiring an in-person visit within 12 months for ongoing telehealth treatment. However, mental health services are exempt from this rule, which means psychiatric care for ADHD typically doesn’t require the annual in-person visit. Additionally, Alabama requires that a licensed medical professional be physically present with the patient during telehealth visits for initial controlled substance prescriptions—though again, this doesn’t apply to Strattera.

Who Can Prescribe ADHD Medications Via Telehealth?

Physicians (MD/DO)

Licensed physicians in all 50 states can prescribe both stimulant and non-stimulant ADHD medications via telehealth, provided they follow DEA registration requirements (for controlled substances) and maintain proper licensure in your state.

Nurse Practitioners and Physician Assistants

The picture is more nuanced for advanced practice providers:

For non-stimulants like Strattera: All states allow nurse practitioners and physician assistants to prescribe non-controlled medications via telehealth under at least a collaborative agreement with a physician. Many states now grant NPs full independent prescribing authority.

For stimulants (Schedule II): Authority varies significantly:

• Independent practice states (New York, Illinois, New Hampshire, California after experience requirements): NPs can prescribe stimulants independently after meeting state-specific training and experience thresholds
• Collaborative practice states (Florida, Pennsylvania, Alabama): NPs and PAs can prescribe Schedule II medications under physician supervision, often with limitations on supply duration
• Restricted states (Georgia, Texas for outpatient, Missouri): NPs cannot prescribe Schedule II drugs at all, or only in very specific settings like hospitals

When working with Klarity Health, you’ll be matched with appropriately credentialed providers licensed in your state—whether that’s a psychiatrist, psychiatric nurse practitioner, or other qualified professional authorized to prescribe ADHD medications in your location. This removes the guesswork about whether your provider has the right credentials.

The Telehealth Evaluation Process

What to Expect During Your Visit

A legitimate ADHD telehealth evaluation isn’t a rubber-stamp process. Expect a comprehensive assessment that includes:

Detailed symptom review: Your provider will ask about attention difficulties, hyperactivity, impulsivity, and how symptoms affect your work, relationships, and daily functioning. They’ll want to know when symptoms started (ADHD by definition begins in childhood, though it may not have been diagnosed then).

Structured questionnaires: Many providers use validated ADHD rating scales like the Adult ADHD Self-Report Scale (ASRS) to systematically assess symptom severity.

Medical and psychiatric history: Your provider needs to know about other conditions, medications, substance use history, cardiovascular health, and family psychiatric history. Conditions like bipolar disorder, active substance use disorders, or significant anxiety may affect treatment decisions.

Rule-out of other causes: Depression, anxiety, sleep disorders, thyroid problems, and other conditions can mimic ADHD. A thorough evaluation distinguishes ADHD from these overlapping issues.

Functional impairment documentation: Providers must confirm that symptoms cause real-world problems—struggles at work or school, relationship difficulties, organizational challenges—not just mild inattention.

This comprehensive approach typically takes 45–60 minutes for an initial evaluation, sometimes longer. If a service promises an ADHD diagnosis and prescription in 10 minutes, that’s a red flag.

Documentation You May Need

Be prepared to provide:

• Previous medical records if you’ve been treated for ADHD before
• School records or report cards showing childhood attention problems
• Collateral information from a parent, spouse, or close contact who can verify symptom history
• List of current medications and any prior ADHD treatment attempts
• Information about accommodations you’ve received (IEP, 504 plan, workplace accommodations)

When Telehealth May Not Be Appropriate

While telehealth works well for many ADHD patients, certain situations warrant in-person evaluation:

• First-time diagnosis in young children (under age 12)
• Complex psychiatric comorbidities requiring stabilization (uncontrolled bipolar disorder, active psychosis, severe eating disorders)
• Acute substance use disorders
• Significant cardiovascular concerns requiring physical examination
• Situations where obtaining accurate history remotely is difficult

Reputable providers will identify these situations and refer you for in-person assessment when appropriate.

Prescription Monitoring and Safety

Prescription Drug Monitoring Programs (PDMPs)

Most states maintain prescription databases that track controlled substances. While Strattera isn’t included in these databases (since it’s not controlled), your provider will likely still review your controlled substance history as part of comprehensive care—especially if you’ve previously taken or might eventually need stimulant medications.

States vary in their PDMP requirements:

• Every prescription: Florida, Alabama, New Hampshire require PDMP checks before each controlled substance prescription
• Periodic checks: California requires checks at least every 4 months for ongoing controlled substance therapy; Pennsylvania every 90 days; Georgia at first prescription then every 90 days
• First prescription only: Some states require only an initial check

For Strattera specifically, these requirements don’t legally apply, but checking your medication history remains good practice to identify potential drug interactions or patterns of concern.

Ongoing Monitoring

Whether you’re prescribed Strattera or another medication, expect regular follow-ups:

Initial phase (first 1–3 months): Visits every 2–4 weeks to assess medication response, adjust dosing, monitor for side effects, and evaluate symptom improvement

Maintenance phase: Monthly to quarterly check-ins once stable on medication, depending on state requirements and clinical needs

What’s monitored: Blood pressure and heart rate (Strattera can increase both), mood changes (FDA requires monitoring for suicidal thoughts especially in youth), liver function if clinically indicated, ADHD symptom response using rating scales, functional improvement in daily life, side effects and tolerability

This ongoing care is crucial for safety and effectiveness. Telehealth providers who prescribe without establishing this follow-up framework are operating outside standard practice.

Comparing Telehealth Platforms: What to Look For

Not all telehealth ADHD services are created equal. Following high-profile investigations into companies like Cerebral and Done in 2022–2023 for allegedly over-prescribing stimulants, the industry has undergone significant scrutiny and reform.

Red Flags to Avoid

• Guaranteed prescriptions: Legitimate providers cannot promise medication before evaluating you
• Minimal evaluation: Any service offering diagnosis and prescription in under 20 minutes
• No video requirement: Audio-only consultations don’t meet standards for controlled substance prescribing and suggest inadequate evaluation
• No follow-up required: Proper ADHD care requires ongoing monitoring
• Pressure to choose stimulants: Providers should discuss both stimulant and non-stimulant options based on your individual situation
• Unwillingness to coordinate care: Reputable services encourage communication with your primary care provider

What Quality Looks Like

Comprehensive evaluation: 45+ minute initial assessments using validated diagnostic tools

Credentialed providers: Licensed physicians or nurse practitioners with appropriate DEA registration and state licensure clearly disclosed

Treatment diversity: Discussion of both medication and non-medication interventions (therapy, coaching, lifestyle modifications)

Structured follow-up: Required regular check-ins with systematic symptom monitoring

Care coordination: Willingness to communicate with your other healthcare providers

Transparent policies: Clear information about costs, insurance acceptance, prescription practices, and state-specific limitations

Klarity Health checks these boxes by matching patients with state-licensed psychiatric providers, requiring comprehensive video evaluations following DSM-5 criteria, offering transparent pricing with both insurance and cash-pay options, and emphasizing ongoing care coordination. With providers available across multiple states, Klarity ensures you can access qualified ADHD care regardless of where you live.

Insurance Coverage and Costs

Telehealth Parity Laws

Most states now require insurance companies to cover telehealth visits at the same rate as in-person visits. However, coverage specifics vary:

Initial evaluation: Typically $150–$300 out-of-pocket without insurance; many insurances cover psychiatric diagnostic evaluations with standard copays/deductibles

Follow-up visits: Usually $75–$150 without insurance; often covered similarly to office visits with insurance

Medication costs:

• Strattera (brand): $300–$400+ per month without insurance
• Atomoxetine (generic): $30–$100 per month without insurance, often $10–$40 with insurance
• Most insurance plans cover generic atomoxetine on their formularies

Cash Pay vs. Insurance

Cash-pay advantages: Predictable costs, no need for pre-authorization, faster appointment availability, complete privacy (no diagnosis codes sent to insurance)

Insurance advantages: Lower per-visit costs after deductible is met, medication coverage can significantly reduce prescription costs, counts toward annual out-of-pocket maximums

Klarity Health accepts both insurance and cash payment, giving you flexibility to choose what works best for your situation. Their transparent pricing model means you’ll know costs upfront—no surprise bills after your visit.

Prior Authorization Challenges

Some insurance plans require prior authorization for ADHD medications, particularly stimulants. This typically involves:

• Submitting clinical documentation of ADHD diagnosis
• Demonstrating that you’ve tried other treatments or that the medication is medically necessary
• Waiting 3–14 days for approval

Strattera advantage: Generic atomoxetine usually doesn’t require prior authorization since it’s not a controlled substance and is generally less expensive than brand-name stimulants. This can mean faster access to treatment.

If prior authorization is denied, your provider can appeal or help you explore alternatives. Some telehealth platforms have dedicated staff to assist with insurance navigation—ask about this when choosing a service.

Special Considerations for Strattera

How Strattera Differs From Stimulants

Mechanism: Strattera is a selective norepinephrine reuptake inhibitor (NRI). It works gradually by increasing norepinephrine availability in the brain, improving attention and impulse control over time.

Timeline: Unlike stimulants that work within 30–60 minutes, Strattera requires 4–6 weeks to reach full therapeutic effect. Initial improvements may appear around week 2–3, but maximum benefit takes patience.

Duration: Provides 24-hour coverage with once-daily dosing. No wearing off in the evening or need for afternoon boosters.

Side effects: Common side effects include decreased appetite, nausea (especially initially), dry mouth, insomnia (take in morning to minimize), increased heart rate and blood pressure (usually mild), sexual side effects in adults, fatigue or drowsiness initially.

FDA warnings: Black box warning for increased risk of suicidal thinking in children and adolescents (monitor closely, especially in first few months). Rare but serious risk of liver injury—report any dark urine, jaundice, or unexplained flu-like symptoms immediately.

Who Benefits Most From Strattera?

Strattera often works well for patients who:

• Need consistent symptom control without fluctuations
• Have comorbid anxiety (stimulants can worsen anxiety; Strattera may help both conditions)
• Experience insomnia or appetite loss with stimulants
• Have tics or Tourette syndrome (stimulants can worsen tics; Strattera is safer)
• Have substance use history making stimulants inadvisable
• Cannot tolerate stimulant side effects
• Prefer avoiding controlled substances
• Need a medication that can be prescribed in 90-day supplies

What to Expect When Starting Strattera

Week 1–2: Possible nausea, decreased appetite, mild fatigue. These often improve. Taking with food can reduce nausea.

Week 2–4: May notice some improvement in focus and impulse control, though not at full effect.

Week 4–6: Therapeutic benefits typically reach plateau. If symptoms aren’t improving by 6–8 weeks at optimal dose, your provider may consider alternatives.

Dose adjustments: Strattera is typically started at lower doses and gradually increased based on response and side effects. This titration process takes several weeks.

Long-term: Once stable, many patients continue Strattera for years with consistent benefit and manageable side effects. Regular monitoring ensures ongoing safety.

Practical Tips for Telehealth ADHD Treatment Success

Before Your First Visit

1. Write down your symptoms and history: When did you first notice attention problems? How do they affect work, relationships, school? What have you already tried?

2. Gather documentation: Locate report cards, previous medical records, or performance reviews that document struggles with attention or organization

3. Prepare questions: What are the risks and benefits of different medications? What happens if the first medication doesn’t work? How will we measure improvement?

4. Check your technology: Ensure your device, camera, and internet connection work properly. Test the video platform beforehand if possible.

5. Create a private, quiet space: Find a location where you can speak openly without interruptions or privacy concerns

During Treatment

1. Be completely honest: Your provider cannot help you effectively without accurate information about symptoms, substance use, medical history, or medication side effects. There’s no judgment—only better care when you’re transparent.

2. Track your symptoms systematically: Keep notes on a scale of 1–10 for focus, impulsivity, mood, sleep, and side effects. This data helps your provider make informed adjustments.

3. Attend all follow-up appointments: Skipping visits puts your continued prescription at risk and compromises your care. Most providers require regular check-ins to maintain ADHD medication prescriptions.

4. Report side effects promptly: Don’t suffer through intolerable side effects waiting for your next scheduled visit. Contact your provider if you experience concerning symptoms.

5. Ask questions: If you don’t understand your treatment plan, medication instructions, or what to expect, speak up. Good providers welcome questions.

Managing Medication

1. Take as prescribed: Even if you feel better, don’t adjust doses or skip days without consulting your provider. Strattera needs consistent daily use to maintain effectiveness.

2. Set reminders: Use phone alarms or pill organizers to remember daily medication, especially important for once-daily medications like Strattera.

3. Plan ahead for refills: Don’t wait until you’re out of medication to request refills. Many patients set calendar reminders a week before they’ll need a refill to account for processing time.

4. Use one pharmacy consistently: This helps pharmacists track your medications and screen for interactions. It also reduces scrutiny that can occur when filling ADHD medications at multiple locations.

5. Store safely: Keep medications in original containers in a secure location, especially if you have children in the home or if prescribed a controlled substance.

When to Seek In-Person Care

Even with excellent telehealth treatment, certain situations warrant transitioning to or consulting with in-person specialists:

• Medication isn’t helping after appropriate trials of multiple options
• Complex psychiatric conditions emerge that require more intensive management
• Side effects are significant or concerning
• You prefer or need physical examinations for other health concerns
• Your life situation changes in ways that affect treatment (pregnancy, new medical diagnoses, relocation to a state where your telehealth provider isn’t licensed)

Quality telehealth providers will recognize these situations and facilitate referrals. This is a sign of good care, not a failure of telehealth.

The Future of ADHD Telehealth

The telehealth landscape for ADHD treatment continues to evolve. While uncertainty exists around long-term DEA policy for controlled substances, several trends point toward sustained and expanded access:

Regulatory maturation: States are moving from temporary emergency rules to permanent telehealth frameworks. Most are maintaining or expanding access rather than restricting it.

Bipartisan support: Telehealth has rare bipartisan backing in Congress, with proposals like the TREATS Act aiming to make cross-state telehealth easier for mental health conditions.

Quality improvements: Industry scrutiny has led to better practices—more thorough evaluations, improved patient screening, better provider training, and enhanced safety protocols.

Technology advances: Better video platforms, integration with electronic health records, and artificial intelligence tools to support (not replace) clinical decision-making are improving care quality.

Patient advocacy: Millions of Americans successfully treated via telehealth during the pandemic have become advocates for maintaining access, creating political pressure for continued flexibility.

For patients seeking non-stimulant ADHD treatment specifically, the future looks particularly stable. Since these medications fall outside DEA control, they’re largely insulated from the regulatory uncertainty affecting stimulants.

Taking the Next Step

If you’re considering telehealth treatment for ADHD—whether with non-stimulants like Strattera, stimulant medications, or a combination approach—understanding your options empowers you to make informed decisions.

Remember these key points:

• Non-stimulant ADHD medications like Strattera can be prescribed via telehealth in all 50 states with minimal restrictions
• Federal and state laws generally support telehealth ADHD treatment, though specific requirements vary by location
• Legitimate telehealth providers conduct comprehensive evaluations similar to in-person assessments
• Quality matters more than convenience—choose providers who prioritize thorough evaluation and ongoing care
• Both stimulant and non-stimulant options have roles in ADHD treatment; the right choice depends on your individual circumstances

Klarity Health connects you with state-licensed psychiatric providers who can evaluate your symptoms, discuss treatment options including both stimulant and non-stimulant medications, and provide ongoing care—all through convenient video visits. With transparent pricing, availability across multiple states, and acceptance of both insurance and cash payment, Klarity removes common barriers to accessing quality ADHD treatment.

Whether you’re seeking an initial diagnosis, looking to try a non-stimulant medication, or need ongoing management of established ADHD, telehealth offers a legitimate, effective pathway to care. Take that first step—your focus, productivity, and quality of life may significantly improve with proper treatment.

Sources

1. DEA Third Temporary Extension of COVID-19 Telemedicine Flexibilities – Federal Register, November 2024. Reported via Fierce Healthcare. Confirms extension of telehealth controlled substance prescribing through December 31, 2025.

2. Sheppard Mullin Healthcare Law Blog – ‘Telehealth and In-Person Visits: Tracking Federal and State Updates to Pandemic-Era Telehealth Exceptions.’ National Law Review, August 15, 2025. Comprehensive 50-state survey of telehealth prescribing rules including New Hampshire SB 252 and state-specific requirements.

3. RxAgent Compliance Blog – ‘The Telehealth Compliance Trap: What Prescribers Must Know About State-by-State Rules.’ October 2025. Details Alabama and New York telehealth restrictions and enforcement risks.

4. Medical News Today – ‘Is Strattera a Controlled Substance?’ January 14, 2025. Medically reviewed explanation that atomoxetine (Strattera) is not a DEA-controlled substance and lacks abuse potential.

5. Center for Connected Health Policy (CCHP) – State telehealth laws database. Accessed November 2025. Official compilation of Florida Statute §456.47, Alabama Board of Medical Examiners telemedicine rules, and other state-specific telehealth prescribing requirements.

Source:

• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20Drug%20Enforcement%20Administration%20,Federal%20Register%20on%20Friday%20night
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=visit,examination%20through%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20%E2%80%9CThird%20Temporary%20Extension%20of,14
• https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance#:~:text=Strattera%20,such%20as%20mental%20health%20issues
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=In%20late%202024%2C%20the%20U,prescribing
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20,False%20Hope
• https://www.techtarget.com/virtualhealthcare/news/366616019/Telehealth-prescribing-flexibility-extended-through-2025#:~:text=Image%20filo%2FDigitalVision%20Vectors%20via%20G,The
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Extend%20natlawreview,before%20issuing%20a%20dangerous%20drug
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=,specifically%20for%20chronic%20pain%20treatment